BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:MEM-288 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of MEM-288\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05076760-2618@assetmemo.bio
DTSTAMP:20261121T005415Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:MEM-288: Phase 1 readout est. (NCT05076760)
DESCRIPTION:MEM-288\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: MEM-288
  Oncolytic Virus Alone and in Combination With Standard of Care Therapy in
  Advanced Solid Tumors\nEstimated primary completion: February 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/mem-288#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05076760
URL:https://assetmemo.bio/drug/mem-288#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
